Publications by authors named "Andres Hernando-Insua"

Claim this Profile
D
Development of bivalent RBD adapted COVID-19 vaccines for broad sarbecovirus immunity.
Laura A Bruno, Celeste Pueblas Castro, Agostina Demaría, Lineia Prado, Clara G Fascetto Cassero

NPJ Vaccines· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Gamma-adapted subunit vaccine induces broadly neutralizing antibodies against SARS-CoV-2 variants and protects mice from infection.
Lorena M Coria, Juan Manuel Rodriguez, Agostina Demaria, Laura A Bruno, Mayra Rios Medrano

Nat Commun· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunomodulatory oligonucleotide IMT504: Effects on mesenchymal stem cells as a first-in-class immunoprotective/immunoregenerative therapy.
Jorge Zorzopulos, Steven M Opal, Andrés Hernando-Insúa, Juan M Rodriguez, Fernanda Elías

World J Stem Cells· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-clinical safety studies of IMT504, a unique non-CpG oligonucleotide.
Raúl Franco, Juan M Rodriguez, Fernanda Elías, Andrés Hernando-Insúa, Juan Fló

Nucleic Acid Ther· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A high dose of IMT504, the PyNTTTTGT prototype immunostimulatory oligonucleotide, does not alter embryonic development in rats.
Andrés Hernando-Insúa, Juan M Rodriguez, Fernanda Elías, Juan Fló, Ricardo López

Oligonucleotides· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oligonucleotide IMT504 reduces neuropathic pain after peripheral nerve injury.
María Florencia Coronel, Andrés Hernando-Insúa, Juan Manuel Rodriguez, Fernanda Elias, Norma Alejandra Chasseing

Neurosci Lett· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IMT504, the prototype of the immunostimulatory oligonucleotides of the PyNTTTTGT class, increases the number of progenitors of mesenchymal stem cells both in vitro and in vivo: potential use in tissue repair therapy.
Andrés Hernando Insúa, Alejandro D Montaner, Juan M Rodriguez, Fernanda Elías, Juan Fló

Stem Cells· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis